Literature DB >> 3028171

Two renal alpha 2-adrenergic receptor sites revealed by p-aminoclonidine binding.

B Sripanidkulchai, R Dawson, S Oparil, J M Wyss.   

Abstract

[3H]p-aminoclonidine [3H]PAC, a specific alpha 2-adrenergic agonist, was used to characterize alpha 2-adrenoceptor binding in rat renal membranes. Rosenthal plots demonstrated two binding sites with Kds of approximately 1.7 and 14.2 nM and Bmaxs (maximum binding) of 47.3 and 218.8 fmol/mg protein for the high- and low-affinity sites, respectively. These characteristics were confirmed by estimate of Kd parameters based on association and dissociation experiments. Pseudo-Hill coefficients generated from drug inhibition experiments were all less than unity, suggesting differential binding at two alpha 2-adrenoceptor binding sites. Specific alpha 2-adrenergic agonists exhibited greater binding affinity to both sites than did nonspecific drugs, and all drugs displayed greater affinity for the high- than the low-affinity binding site. Both guanyl nucleotides and sodium chloride inhibited [3H]PAC binding more at the high-affinity than at the low-affinity site. Renal denervation resulted in significant upregulation of receptor density only at the high-affinity sites with no change in receptor affinity at either site, suggesting that a majority of the alpha 2-adrenoceptors in the kidney are postsynaptic. Thus all lines of evidence in this study indicate that two alpha 2-adrenoceptor binding sites exist in the rat kidney.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3028171     DOI: 10.1152/ajprenal.1987.252.2.F283

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  1 in total

1.  Dexamethasone Causes Hypertension in Rats Even Under Chemical Blockade of Peripheral Sympathetic Nerves.

Authors:  Alexandra E Soto-Piña; Cynthia Franklin; C S Sheela Rani; Elizabeth Fernandez; Elías Cardoso-Peña; Alejandra D Benítez-Arciniega; Helmut Gottlieb; Carmen Hinojosa-Laborde; Randy Strong
Journal:  Front Neurosci       Date:  2019-12-06       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.